These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 21478264)

  • 1. Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer.
    Vaneycken I; Devoogdt N; Van Gassen N; Vincke C; Xavier C; Wernery U; Muyldermans S; Lahoutte T; Caveliers V
    FASEB J; 2011 Jul; 25(7):2433-46. PubMed ID: 21478264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT.
    Gainkam LO; Huang L; Caveliers V; Keyaerts M; Hernot S; Vaneycken I; Vanhove C; Revets H; De Baetselier P; Lahoutte T
    J Nucl Med; 2008 May; 49(5):788-95. PubMed ID: 18413403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro analysis and in vivo tumor targeting of a humanized, grafted nanobody in mice using pinhole SPECT/micro-CT.
    Vaneycken I; Govaert J; Vincke C; Caveliers V; Lahoutte T; De Baetselier P; Raes G; Bossuyt A; Muyldermans S; Devoogdt N
    J Nucl Med; 2010 Jul; 51(7):1099-106. PubMed ID: 20554727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. (99m)Tc-maEEE-Z(HER2:342), an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors.
    Tran T; Engfeldt T; Orlova A; Sandström M; Feldwisch J; Abrahmsén L; Wennborg A; Tolmachev V; Karlström AE
    Bioconjug Chem; 2007; 18(6):1956-64. PubMed ID: 17944527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 Nanobodies for iPET imaging of HER2 receptor expression in cancer.
    Xavier C; Vaneycken I; D'huyvetter M; Heemskerk J; Keyaerts M; Vincke C; Devoogdt N; Muyldermans S; Lahoutte T; Caveliers V
    J Nucl Med; 2013 May; 54(5):776-84. PubMed ID: 23487015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Dye and Conjugation Chemistry on the Biodistribution Profile of Near-Infrared-Labeled Nanobodies as Tracers for Image-Guided Surgery.
    Debie P; Van Quathem J; Hansen I; Bala G; Massa S; Devoogdt N; Xavier C; Hernot S
    Mol Pharm; 2017 Apr; 14(4):1145-1153. PubMed ID: 28245129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation and characterization of nanobodies targeting PSMA for molecular imaging of prostate cancer.
    Evazalipour M; D'Huyvetter M; Tehrani BS; Abolhassani M; Omidfar K; Abdoli S; Arezumand R; Morovvati H; Lahoutte T; Muyldermans S; Devoogdt N
    Contrast Media Mol Imaging; 2014; 9(3):211-20. PubMed ID: 24700748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A kit to prepare (111)In-DTPA-trastuzumab (Herceptin) Fab fragments injection under GMP conditions for imaging or radioimmunoguided surgery of HER2-positive breast cancer.
    Scollard DA; Chan C; Holloway CM; Reilly RM
    Nucl Med Biol; 2011 Jan; 38(1):129-36. PubMed ID: 21220136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of the Tumor-Specific Antigen-Derived Synthetic Peptides as Potential Candidates for Targeting Breast and Other Possible Human Carcinomas.
    Okarvi SM; AlJammaz I
    Molecules; 2019 Aug; 24(17):. PubMed ID: 31470531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SPECT/CT Imaging of the Novel HER2-Targeted Peptide Probe
    Li L; Wu Y; Wang Z; Jia B; Hu Z; Dong C; Wang F
    J Nucl Med; 2017 May; 58(5):821-826. PubMed ID: 28104744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring therapeutic response of human ovarian cancer to trastuzumab by SPECT imaging with (99m)Tc-peptide-Z(HER2:342).
    Zhang J; Zhao X; Wang S; Wang N; Han J; Jia L; Ren X
    Nucl Med Biol; 2015 Jun; 42(6):541-6. PubMed ID: 25735223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kit formulation for 99mTc-labeling of recombinant anti-HER2 Affibody molecules with a C-terminally engineered cysteine.
    Ahlgren S; Andersson K; Tolmachev V
    Nucl Med Biol; 2010 Jul; 37(5):539-46. PubMed ID: 20610158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of
    Rainone P; Riva B; Belloli S; Sudati F; Ripamonti M; Verderio P; Colombo M; Colzani B; Gilardi MC; Moresco RM; Prosperi D
    Int J Nanomedicine; 2017; 12():3447-3461. PubMed ID: 28496321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma.
    Keyaerts M; Xavier C; Heemskerk J; Devoogdt N; Everaert H; Ackaert C; Vanhoeij M; Duhoux FP; Gevaert T; Simon P; Schallier D; Fontaine C; Vaneycken I; Vanhove C; De Greve J; Lamote J; Caveliers V; Lahoutte T
    J Nucl Med; 2016 Jan; 57(1):27-33. PubMed ID: 26449837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of [
    Ducharme M; Hall L; Eckenroad W; Cingoranelli SJ; Houson HA; Jaskowski L; Hunter C; Larimer BM; Lapi SE
    Mol Pharm; 2023 Sep; 20(9):4629-4639. PubMed ID: 37552575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted radionuclide therapy with A 177Lu-labeled anti-HER2 nanobody.
    D'Huyvetter M; Vincke C; Xavier C; Aerts A; Impens N; Baatout S; De Raeve H; Muyldermans S; Caveliers V; Devoogdt N; Lahoutte T
    Theranostics; 2014; 4(7):708-20. PubMed ID: 24883121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models.
    Kirpotin DB; Drummond DC; Shao Y; Shalaby MR; Hong K; Nielsen UB; Marks JD; Benz CC; Park JW
    Cancer Res; 2006 Jul; 66(13):6732-40. PubMed ID: 16818648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular imaging with macrophage CRIg-targeting nanobodies for early and preclinical diagnosis in a mouse model of rheumatoid arthritis.
    Zheng F; Put S; Bouwens L; Lahoutte T; Matthys P; Muyldermans S; De Baetselier P; Devoogdt N; Raes G; Schoonooghe S
    J Nucl Med; 2014 May; 55(5):824-9. PubMed ID: 24686780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preparation and
    Okarvi SM; Aljammaz I
    Anticancer Res; 2018 May; 38(5):2823-2830. PubMed ID: 29715105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective cytotoxicity to HER2-positive tumor cells by a recombinant e23sFv-TD-tBID protein containing a furin cleavage sequence.
    Wang F; Ren J; Qiu XC; Wang LF; Zhu Q; Zhang YQ; Huan Y; Meng YL; Yao LB; Chen SY; Xu YM; Yang AG
    Clin Cancer Res; 2010 Apr; 16(8):2284-94. PubMed ID: 20371697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.